[Prospective randomized controlled study of bestatin in gastric cancer surgery].
The effectiveness of bestatin combined with mitomycin C and tegafur as an adjuvant to surgery for gastric cancer was investigated in a prospective randomized controlled study. All patients underwent curative gastrectomy during the period from November 1980 to April 1984. Five-year survival rate revealed no significant difference between groups with or without bestatin. The effectiveness of bestatin was suggested in postoperative peritoneal recurrence in cases with positive histological invasion into the veins of the stomach wall.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007930:Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D011182:Postoperative Care; D011379:Prognosis; D011446:Prospective Studies; D011897:Random Allocation; D013274:Stomach Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D005641:Tegafur / Q000008:administration & dosage
D000276:Adjuvants, Immunologic; D008937:Mitomycins; D005641:Tegafur; D016685:Mitomycin; D007930:Leucine; C012211:ubenimex